Were Susan Bobulsky’s ADPT share sales made under a Rule 10b5-1 trading plan?

Yes, the reported sales were effected under a Rule 10b5-1 trading plan . A footnote states the plan was adopted on December 16, 2025 , and all transactions in this Form 4 were carried out pursuant to that trading plan.

Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 5,000 shares in plan

Q: What insider transaction did Adaptive Biotechnologies (ADPT) officer Susan Bobulsky report?

Susan Bobulsky reported a sale of 5,000 shares of Adaptive Biotechnologies Common Stock. The transaction occurred on July 16, 2026 at a price of $23.00 per share and was executed under a Rule 10b5-1 trading plan .

Q: At what price did Susan Bobulsky sell her ADPT shares?

She sold her ADPT Common Stock at $23.00 per share . The Form 4 shows a single non-derivative transaction on July 16, 2026 classified as a sale in an open market or private transaction, covering a total of 5,000 shares .

Q: How many Adaptive Biotechnologies (ADPT) shares does Susan Bobulsky hold after this sale?

After the reported sale, Susan Bobulsky directly holds 401,288 shares of Adaptive Biotechnologies Common Stock. This post-transaction balance reflects her remaining direct ownership following the 5,000-share sale reported for July 16, 2026.

Q: When was Susan Bobulsky’s Rule 10b5-1 trading plan for ADPT shares adopted?

Her Rule 10b5-1 trading plan was adopted on December 16, 2025 . According to the footnote, the July 16, 2026 sale of 5,000 shares at $23.00 per share was executed pursuant to this pre-established trading plan.

Q: What type of security did Susan Bobulsky trade in the ADPT Form 4 filing?

She traded Common Stock of Adaptive Biotechnologies Corp. The Form 4 lists one non-derivative transaction: a sale of 5,000 shares of Common Stock at $23.00 per share , leaving her with 401,288 directly held Common shares.

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, sold 5,000 shares of Common Stock on July 16, 2026 at $23.00 per share. The sale was made under a Rule 10b5-1 trading plan adopted on December 16, 2025, and she now directly holds 401,288 shares of Common Stock.

Insider Trade Summary 10b5-1

Net Seller: 5,000 shares

Net Sell 1 txn

Insider BOBULSKY SUSAN

Role Chief Commercial Officer, MRD

Sold 5,000 shs ($115K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^F1	5,000	$23.00	$115K

Holdings After Transaction: Common Stock — 401,288 shares (Direct)

Footnotes (1)

F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

Key Figures

Shares sold: 5,000 shares Sale price per share: $23.00 Shares owned after sale: 401,288 shares +2 more

5 metrics

Shares sold 5,000 shares Common Stock sale on July 16, 2026

Sale price per share $23.00 Price per share for Common Stock sold

Shares owned after sale 401,288 shares Direct Common Stock holdings following transaction

Net shares sold in filing 5,000 shares Net of all reported transactions in this Form 4

10b5-1 plan adoption date December 16, 2025 Date Rule 10b5-1 trading plan was adopted

Key Terms

Rule 10b5-1 trading plan, Common Stock, Sale in open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"transactions reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Common Stock financial

"security_title: Common Stock for the reported non-derivative transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Sale in open market or private transaction market

"transaction_code_description: Sale in open market or private transaction"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/20/2026 - 07:20 PM Accepted by SEC EDGAR 07/20/2026 - 07:19 PM

FAQ

What insider transaction did Adaptive Biotechnologies (ADPT) officer Susan Bobulsky report?

Susan Bobulsky reported a sale of 5,000 shares of Adaptive Biotechnologies Common Stock. The transaction occurred on July 16, 2026 at a price of $23.00 per share and was executed under a Rule 10b5-1 trading plan.

At what price did Susan Bobulsky sell her ADPT shares?

She sold her ADPT Common Stock at $23.00 per share. The Form 4 shows a single non-derivative transaction on July 16, 2026 classified as a sale in an open market or private transaction, covering a total of 5,000 shares.

How many Adaptive Biotechnologies (ADPT) shares does Susan Bobulsky hold after this sale?

After the reported sale, Susan Bobulsky directly holds 401,288 shares of Adaptive Biotechnologies Common Stock. This post-transaction balance reflects her remaining direct ownership following the 5,000-share sale reported for July 16, 2026.

When was Susan Bobulsky’s Rule 10b5-1 trading plan for ADPT shares adopted?

Her Rule 10b5-1 trading plan was adopted on December 16, 2025. According to the footnote, the July 16, 2026 sale of 5,000 shares at $23.00 per share was executed pursuant to this pre-established trading plan.

What type of security did Susan Bobulsky trade in the ADPT Form 4 filing?

She traded Common Stock of Adaptive Biotechnologies Corp. The Form 4 lists one non-derivative transaction: a sale of 5,000 shares of Common Stock at $23.00 per share, leaving her with 401,288 directly held Common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOBULSKY SUSAN

(Last)

(First)

(Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVENUE EAST

(Street)

SEATTLE

WASHINGTON

98109

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Commercial Officer, MRD

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/16/2026		S⁽¹⁾		5,000	D	$23	401,288	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 16, 2025.

	Susan Bobulsky by Kyle Piskel, Attorney-in-Fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR